| Dr Gretta Shara, DPM | |
|
23064 E Main St, Armada, MI 48005-4705 | |
| (586) 784-0184 | |
| (586) 784-5227 |
| Full Name | Dr Gretta Shara |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 31 Years |
| Location | 23064 E Main St, Armada, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679535942 | NPI | - | NPPES |
| P00301345 | Other | MI | MEDICARE RAILROAD PIN |
| 4855001230 | Other | MI | BLUE CROSS BLUE SHIELD |
| 383335188 | Other | MI | COMERCIAL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 5901001789 (Michigan) | Secondary |
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 5901001789 (Michigan) | Primary |
| Provider Name | Gretta Shara, Dpm, Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1003074089 PECOS PAC ID: 7416020292 Enrollment ID: O20080728000172 |
News Archive
Neuraltus Pharmaceuticals, a private biopharmaceutical company developing novel therapies for rare neurological disorders, announced today top-line results from the Company's Phase 2 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).
Measuring five quality-base performance areas, an ambulatory surgical center out performed a standard hospital based surgical center in otolaryngic surgeries, according to new research in the December 2009 issue of Otolaryngology - Head and Neck Surgery.
The current COVID-19 pandemic is caused by a novel coronavirus called SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2.
AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that tivozanib demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gretta Shara, DPM Po Box 907, Armada, MI 48005-0907 Ph: (586) 784-0184 | Dr Gretta Shara, DPM 23064 E Main St, Armada, MI 48005-4705 Ph: (586) 784-0184 |
News Archive
Neuraltus Pharmaceuticals, a private biopharmaceutical company developing novel therapies for rare neurological disorders, announced today top-line results from the Company's Phase 2 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).
Measuring five quality-base performance areas, an ambulatory surgical center out performed a standard hospital based surgical center in otolaryngic surgeries, according to new research in the December 2009 issue of Otolaryngology - Head and Neck Surgery.
The current COVID-19 pandemic is caused by a novel coronavirus called SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2.
AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that tivozanib demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma.
› Verified 9 days ago
Armada Foot And Ankle Clinic Podiatrist Medicare: Medicare Enrolled Practice Location: 23064 E Main St, Armada, MI 48005 Phone: 586-784-0184 Fax: 586-784-5227 |